Introduced to the UK in approximately 2011 and manufactured by the French company Vivacy Laboratories, Stylage® is the first hyaluronic acid dermal filler with local anaesthetic lidocaine (lignocaine) and an antioxidant, in the form of mannitol, all within one product. The presence of mannitol, the "free radical scavenger", limits the devastating effects of free radicals on the dermis and product injected, thus reducing the risk of post-injection inflammation and preventing the gel's structure degradation.
With their patented IPN-like® Technology (Interpenetrated Network), Vivacy has created something which has two structures—the monophasic A and B structure, and the IPN-like structure. The two are mechanically independent, so Stylage is easy to inject and the increased density of its cross-linking nodes make it long-lasting. This methods requires less BDDE (a common compound used in cross linking hyauronic acids) which the company claims is more effective and results in a safer, longer lasting product.
Stylage® XL is injected into the deep dermis or subcutaneous layer for the treatment of facial volume defects, the restoration of facial contours, cheekbone area augmentation and the treatment of slight facial ptosis (skin sagging). Stylage® XL is also indicated for the treatment of facial lipodystrophy, including patients suffering from HIV. Stylage® XL can also be used in techniques for rejuvenating the hands by sub-cutaneous injection in the back of the hand.
The duration of the effect of a Stylage® XL treatment is 12 months and more. It's very individual and depends on many factors, such as the patient's skin type and structure, age, lifestyle, the area treated and the injection technique used by the practitioner.
Stylage® XL is injection into deep dermal
Cross-linked hyaluronic acid IPN-Like: 26 mg/g
Mannitol q.s. 1g
Phosphate buffer pH: 7,2
2 x 1 ml prefilled syringe
needles: 2 x 27G 1/2, 2 x 23G 1 1/4
Read the package leaflet before use.